No International Reference Pricing for drugs in the US – good news for patients in the US and worldwide
The US Government just published its “Comprehensive Plan for Addressing High Drug Prices”. It lists a number of initiatives and ideas, but does NOT mention is International Reference Pricing – and this is good news for patients in the US and worldwide (and for manufacturers, too). – Read the Akceso Advisors reflection on a latest development in the US pharmaceuticals market based on Akceso Advisors’ research related to the impact of International Reference Pricing (IRP) on patient access and innovation.
